Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibiting the development of tolerance to and/or dependence on an addictive substance

a technology of addictive substances and tolerance, applied in the field of addictive substances, can solve the problems of toxicity of mk-801, unsuitable pharmaceutical use, limited long-term administration, etc., and achieve the effect of alleviating withdrawal symptoms and reducing withdrawal symptoms

Inactive Publication Date: 2006-09-19
VIRGINIA COMMONWEALTH UNIV MEDICAL COLLEGE
View PDF74 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006]Still further in accordance with this invention, a method of alleviating withdrawal symptoms in a mammal addicted to an addictive substance is provided which comprises administering to the addicted mammal the addictive substance before, with or following administration to the mammal

Problems solved by technology

Morphine is a rapid and effective drug for the treatment of severe pain but its long term administration has been limited due to its negative side effects, principally tolerance and dependence, which develop rapidly after administration.
However, MK-801 has been found to be toxic and is therefore unsuitable for pharmaceutical use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibiting the development of tolerance to and/or dependence on an addictive substance
  • Inhibiting the development of tolerance to and/or dependence on an addictive substance
  • Inhibiting the development of tolerance to and/or dependence on an addictive substance

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0031]The effect of systemic dextrorphan on prevention of the development of morphine tolerance and dependence was examined in Sprague-Dawley rats weighing 350-400 gm. Morphine tolerance was developed in the rats by twice daily subcutaneous injection of 10 mg / kg morphine sulfate. The analgesic effect of the morphine was examined by using the well known tail-flick test which measures the latency of tail-flick upon radiant heat stimulation. The latency of tail-flick test is defined as the time elapsed from the onset of radiant heat to the flick of the rat's tail. In order to examine the effect of dextrorphan on the development of morphine tolerance, each morphine-treated rat also received intraperitoneal administration of either dextrorphan (1.56, 3.13, 6.25, 12.5 mg / kg, n=5 / group) or saline (n=6) given 30 minutes prior to each morphine administration.

[0032]FIG. 1 shows the effects of systemic doses of dextrorphan (DEX) on tolerance to morphine analgesia produced by twice daily subcut...

example 2

[0034]The effects of ganglioside GM1 in inhibiting morphine tolerance and dependence utilizing both systemic and intrathecal treatment were evaluated. The systemic treatment procedure, including both morphine and ganglioside GM1 administration, was exactly the same as that used in the experimental work presented in Example 1 except that ganglioside GM1 was given 1 hour before each morphine administration.

[0035]As shown in FIG. 3, the tail flick latency in ganglioside GM1-treated (10, 30, 60 mg / kg, n=6 / group) rats remained significantly longer than that of saline-treated rats on days 5, 7, 9, and 10 of repeated morphine administration, indicating the prevention of the development of morphine tolerance by ganglioside GM1. Although all 3 doses of ganglioside GM1 were effective, 30 and 60 mg / kg were more effective at days 9 and 10 than 10 mg / kg.

[0036]FIG. 4 shows the effects of systemic doses of ganglioside GM1 on jumping, a withdrawal symptom produced by subcutaneous naloxone (2 mg / kg)...

example 3

[0037]This example demonstrates the effectiveness of ganglioside GM1 in preventing the development of morphine tolerance at the site of the spinal cord. Morphine sulfate 10 μg was delivered once daily through an intrathecal (spinal) canula implanted 5 days before the first morphine injection. Ganglioside GM1 or saline also was delivered intrathecally 30 minutes before each morphine injection.

[0038]FIG. 5 shows the effects of the intrathecal doses of ganglioside GM1 on tolerance to morphine analgesia produced by once daily intrathecal administration of 10 μg morphine. Intrathecal ganglioside GM1 was given 30 min before each morphine administration. Each symbol represents mean scores for maximal possible effects (and hence analgesia) for each group of rats (n=5-6) measured at 15, 30, 60, 90, 120, 180, and 240 minutes after morphine injection on Day 8, i.e., 24 hours following 6 consecutive daily intrathecal morphine injections. Vertical bars are standard errors. Maximal possible effec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA-receptor activation, e.g., a ganglioside such as GM1 or GT1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and / or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.

Description

CROSS REFERENCE TO RELATED APPLICATION[0001]This is a continuation of application Ser. No. 08 / 043,280 filed Apr. 6, 1993, now U.S. Pat. No. 5,321,012, which is a continuation-in-part of U.S. patent application Ser. No. 08 / 010,583, filed Jan. 28, 1993, abandoned.BACKGROUND OF THE INVENTION[0002]This invention relates to a composition containing an addictive substance and a component which inhibits the development of tolerance to and / or dependence on the addictive substance. More particularly, the invention relates to a composition containing an addictive substance such as morphine or codeine and at least one nontoxic substance that blocks the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that blocks at least one major intracellular consequence of NMDA receptor activation, e.g., a ganglioside such as ganglioside GM1 or GT1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/70A61K31/44A61K31/445A61K31/54A61K31/485
CPCA61K31/485
Inventor MAYER, DAVID J.MAO, JIANREN
Owner VIRGINIA COMMONWEALTH UNIV MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com